Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 6, 2016

Daiichi Sankyo and partners to research on capillary stem cells

Daiichi Sankyo has entered into a research collaboration with Mitsubishi UFJ Capital and Asahikawa Medical University to develop new capillary stem cells (CapSCs) into a cell source for regenerative medicine and cell therapy.

Daiichi Sankyo has entered into a research collaboration with Mitsubishi UFJ Capital and Asahikawa Medical University to develop new capillary stem cells (CapSCs) into a cell source for regenerative medicine and cell therapy.

CapSCs have been discovered by the joint research of Asahikawa Medical University and Asubio Pharma, a wholly owned subsidiary of Daiichi Sankyo.

These cells can be differentiated into both blood vessels and various tissue cells.

During the research, the practical use of CapSC as a source for cell therapy will be investigated, besides the therapeutic effects.

"A new company, known as OiDE CapiSEA, has been established to carry out the three-year joint research."

A new company, known as OiDE CapiSEA, has been established to carry out the three-year joint research.

This new company is funded by OiDE Fund Investment Limited Partnership (OiDE Fund), operated by Mitsubishi UFJ Capital.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

Upon achieving the goals of the research, Daiichi Sankyo will purchase all the stocks of CapiSEA to continue research and development as its own project, and will pay a fee to Asahikawa Medical University depending on advances in both these areas.

Asahikawa Medical University will also hold some stocks as consideration.

Daiichi Sankyo and Mitsubishi UFJ Capital have committed to continue to promote open innovation activities to develop a new drug discovery platform technology using the OiDE Fund.

Additionally, Daiichi Sankyo has reached a clinical collaboration agreement with Portola Pharmaceuticals to develop andexanet alfa as an antidote for edoxaban, Daiichi Sankyo’s Factor Xa inhibitor, in Japan.

As per the agreed terms, Portola will receive an upfront payment and is eligible to receive an additional milestone payment based on Japanese Ministry of Health, Labor and Welfare (MHLW) approval of andexanet alfa as an antidote for edoxaban.

Daiichi Sankyo has agreed to provide technical support and fund all clinical studies of andexanet alfa with edoxaban in Japan.

However, it will not receive commercial or financial rights under this agreement.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU